A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Somatic hypermutation (SHM) introduces point mutations into variable region genes at ~1 per 10³ base pairs per cell division, generating high-affinity variants. SHM is targeted to immunoglobulin genes by activation-induced deaminase (AID). High-affinity B cells are selected for survival in germinal centers through competition for antigen-antibody complexes on follicular dendritic cells.
You know from studying antibody structure that each B cell produces immunoglobulin with a unique antigen-binding site, and from B cell development that this initial diversity is generated by V(D)J recombination in the bone marrow. But the antibodies produced during an initial immune response are often mediocre binders — good enough to recognize the pathogen, but far from optimal. Affinity maturation is the process by which the immune system improves antibody quality after infection, producing antibodies that bind their target tens to hundreds of times more tightly than the originals. This happens inside specialized microenvironments called germinal centers within secondary lymphoid organs.
The engine of affinity maturation is somatic hypermutation (SHM), a process that introduces point mutations into the variable region genes of immunoglobulin at an extraordinarily high rate — roughly one mutation per thousand base pairs per cell division, which is about a million times higher than the normal background mutation rate. This targeted mutagenesis is initiated by the enzyme activation-induced cytidine deaminase (AID), which converts cytosine residues to uracil in the DNA of actively transcribed immunoglobulin genes. The resulting U:G mismatches are then processed by error-prone repair pathways that introduce mutations at and around the original deamination site. AID is specifically recruited to immunoglobulin loci through features of their transcription, which is why SHM is targeted rather than genome-wide — a critical safety feature, since random mutagenesis across the genome would be catastrophic.
The mutations generated by SHM are random with respect to whether they improve or worsen antigen binding. Most mutations are neutral or harmful — they may disrupt the folding of the variable domain or reduce affinity for the antigen. The key is what happens next: selection. In the germinal center, mutated B cells must compete for limited antigen displayed on the surface of follicular dendritic cells (FDCs). B cells whose mutated receptors bind antigen more tightly capture more antigen, process it, and present more peptide-MHC complexes to follicular helper T cells (Tfh). Tfh cells, in turn, provide survival signals — CD40L engagement and IL-21 — proportional to the amount of antigen presented. B cells with the highest affinity receptors receive the strongest survival signals and are selected to proliferate, while those with lower affinity die by apoptosis. This is essentially Darwinian evolution operating within a single organism over days rather than generations.
The result is dramatic. Over successive rounds of mutation and selection — B cells cycle between the dark zone (where they proliferate and mutate) and the light zone (where they are selected) — average antibody affinity increases by 10- to 100-fold. This is why a secondary immune response is not just faster but qualitatively better: memory B cells generated from germinal centers carry high-affinity, somatically mutated receptors that can neutralize pathogens far more effectively than the naive B cells that initiated the first response. Affinity maturation also explains why repeated vaccination boosts antibody quality, not just quantity — each exposure drives additional rounds of selection for ever-higher affinity variants.